Cytori Therapeutics Inc. (NASDAQ:CYTX)’s share price shot up 7.4% on Friday . The company traded as high as $2.05 and last traded at $2.02, with a volume of 134,150 shares traded. The stock had previously closed at $1.88.

A number of research firms have recently weighed in on CYTX. Zacks Investment Research cut shares of Cytori Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 4th. Maxim Group set a $5.00 price target on shares of Cytori Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 5th. Finally, Roth Capital reaffirmed a “buy” rating and set a $11.00 price target on shares of Cytori Therapeutics in a research note on Tuesday, June 28th.

The firm’s market cap is $27.01 million. The company has a 50 day moving average of $2.04 and a 200-day moving average of $2.80.

Cytori Therapeutics (NASDAQ:CYTX) last posted its earnings results on Thursday, August 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by $0.04. The business earned $1.10 million during the quarter, compared to the consensus estimate of $2.50 million. The business’s revenue was down 31.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.06) EPS. Equities research analysts anticipate that Cytori Therapeutics Inc. will post ($1.59) earnings per share for the current fiscal year.

Cytori Therapeutics, Inc (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns combined with radiation injury.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.